The Medical Letter on Drugs and Therapeutics
Spritam - A New Formulation of Levetiracetam for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug levetiracetam (Spritam – Aprecia) for adjunctive treatment of partial-onset, myoclonic, and primary generalized tonic-clonic seizures. Oral and intravenous formulations of levetiracetam (Keppra, and generics) have been available for years. Although approved by the FDA only as adjunctive therapy, levetiracetam is commonly used as monotherapy for partial-onset and generalized seizures and may also be effective in treating absence seizures and seizures of Lennox-Gastaut syndrome.1

THE NEW FORMULATION – Spritam is the first drug to be manufactured in the US using 3D printing technology. During manufacturing, the 3D printer dispenses powdered medication in layers and a liquid binding agent that binds the layers together. Since no compression forces are used ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Spritam - A New Formulation of Levetiracetam for Epilepsy
Article code: 1497b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian